Showing 4361-4370 of 8850 results for "".
- Enspectra Health Awarded NIH Grant to Advance Predictive Algorithms for AKshttps://practicaldermatology.com/news/enspectra-health-awarded-nih-grant-to-advance-predictive-algorithms-for-aks/2461874/Enspectra Health scored $2M in grant funding from the National Cancer Institute (NCI) to support research for developing deep learning algorithms to predict which actinic keratosis (AK) lesions, are likely to progress to squamous cell carcinoma (SCC). Enspectra's technolog
- Revian Red Hair Growth System Takes on CCCA in Second Studyhttps://practicaldermatology.com/news/revian-red-hair-growth-system-takes-on-ccca-in-second-study/2461864/Revian Red Hair Growth System is planning a second study to build on previous trial results as an effective treatment for Central Centrifugal Cicatricial Alopecia (CCCA). The Revian Red Hair Growth System is a US Foof and Drug Administration- cleared, lightweight wirel
- DermTech Adds Approximately 7 Million Covered Lives for the Foundational Assay of Its Melanoma Testhttps://practicaldermatology.com/news/dermtech-adds-approximately-7-million-covered-lives-for-the-foundational-assay-of-its-melanoma-test/2461861/DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced a favorable coverage policy from Highmark Inc. (Highmark). Highmark and its Blue-branded affiliates provide health insurance to approximately 7 million members in Pennsylvania, We
- Novel Peptide T14 May Reflect Age and Photoaging in Human Skinhttps://practicaldermatology.com/news/novel-peptide-t14-may-reflect-age-and-photo-aging-in-human-skin/2461843/A novel peptide ‘T14’ may reflect age and photoaging in human skin, according to a study in Aging. T14 is a 14mer peptide derived from the C-terminus of acetylcholinesterase (AChE). Once cleav
- NY Dermatologist Louise Kaufmann, MD, Wins an International Award for Social Responsibility in Dermatology from L’Oréal and ILDShttps://practicaldermatology.com/news/dr-louise-kaufmann-wins-an-international-awards-for-social-responsibility-in-dermatology-from-loreal-and-ilds/2461842/Louise Kaufmann, MD, a general and cosmetic dermatologist in Great Neck, New York, took home an International Award for Social Responsibility in Dermatology for her efforts to provide access to dermatological care in rural and underserved areas of Jamaica. The awards, sp
- Biosimilar Update: Fresenius Kabi’s Idacio Joins Growing List of Available Humira Biosimilarshttps://practicaldermatology.com/news/biosimilar-update-fresenius-kabis-idacio-joins-growing-list-of-available-humira-biosimilars/2461836/Fresenius Kabi’s citrate-free adalimumab biosimilar
- Biosimilar News: Another Humira Biosimilar Enters US Markethttps://practicaldermatology.com/news/biosimilar-news-another-humira-biosimilar-enters-us-market/2461835/Biocon Biologics Ltd’s HULIO (adalimumab-fkjp) injection, a biosimilar to Humira (adalimumab), is now available in the United States after five years of experience in Europe and two years in Canada. "The launch of HULIO, our biosim
- HS Pipeline Update: HS Patients Taking Nanobody Sonelokimab Hit HiSCR 75 as Early as Week 12https://practicaldermatology.com/news/hs-pipeline-update-hs-patients-taking-nanobody-sonelokimab-hit-hiscr-75-as-early-as-week-12/2461806/Nanobody Sonelokimab is looking good in patients with moderate-to-severe hidradenitis suppurativa (HS), according to topline Phase 2 results from MoonLake Immunotherapeutics. Nanobodies are antibody-derived targeted therapies. They consist of one or more domains based on
- Zydus Lifesciences Scores FDA Nod for Generic Acne Drughttps://practicaldermatology.com/news/zydus-lifesciences-scores-fda-nod-for-generic-acne-drug/2461791/The U.S. Food and Drug Administration (FDA) has given its nod to Zydus Lifesciences’ generic antibiotic minocycline hydrochloride extended-release tablets for the treatment of moderate to severe acne in 55 mg, 65 mg, and 115 mg doses, the Company reports. Minocycline hyd
- Cutera's AviClear Scores FDA Nod as Long-Term Acne Treatmenthttps://practicaldermatology.com/news/cuteras-aviclear-scores-fda-nod-as-long-term-acne-treatment/2461784/The U.S. Food and Drug Administration (FDA) has cleared AviClear as a long-term treatment for mild to severe inflammatory acne vulgaris. Cutera’s AviClear initially received FDA clearance for treating acne in March 2022. Now, the FDA has cleared the device for the long